Pharnext SCA

ALPHA

FR001400N1P4

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:35:00 2024-04-26 am EDT			5-day change	1st Jan Change
0.1499 ^EUR	-8.88%		-12.75%	-92.50%

Apr. 25	Pharnext: share price rises on encouraging comments	CF
Mar. 06	Pharnext: listing suspended pending further update	CF

Pharnext SA announced that it expects to receive ?1.5 million in funding

December 04, 2023

Pharnext SA announces private placement of ?1,500,000 through the issue of Oceane-BSA on December 5, 2023. The placement has been subscribed by Global Tech Opportunities 13.

Latest news about Pharnext SCA

Pharnext: share price rises on encouraging comments	Apr. 25	CF
Pharnext: listing suspended pending further update	Mar. 06	CF
Global markets live: BAE Systems, HSBC, Nvidia, Tesla, Boeing...	Feb. 21
Pharnext SA announced that it has received ?41.188458 million in funding	Jan. 30	CI
Pharnext launches drastic cost-cutting plan	Jan. 17	CF
Pharnext Unveils Cost Reduction Plan, to Continue Development of Neurological Disorder Drug	Jan. 17	MT
Pharnext: registration dossiers prepared for Charcot disease	Dec. 19	CF
Pharnext: share price falls after disappointing clinical study	Dec. 11	CF
Pharnext SA announced that it expects to receive ?1.5 million in funding	Dec. 04	CI
Pharnext: phase III study data frozen	Dec. 04	CF
Pharnext Delays Exclusivity Agreement for Peripheral Nerve Disease Drug; Shares Sink	Nov. 27	MT
Pharnext: fundraising, new trading calendar	Nov. 27	CF
Pharnext: Phase III results expected on December 11	Nov. 23	CF
Pharnext: share price rises, milestone achieved in the USA	Nov. 20	CF
Pharnext Manufactures US Registration Batches of Oral Solution Ahead of FDA Application	Nov. 20	MT
Pharnext SA announced that it has received ?0.5 million in funding	Nov. 15	CI
Pharnext SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-30	CI
Pharnext: new offer from a top-10 player	23-10-30	CF
Pharnext Shares Soar on EUR510 Million Offer for Neuropathy Drug Candidate	23-10-30	MT
Neovacs: boosted by the Pharnext dossier	23-10-23	CF
Pharnext Shares Surge Amid EUR250 Million Offers for Main Drug Candidate	23-10-16	MT
Pharnext: share price back down after fundraising	23-09-22	CF
Pharnext Stock Skyrockets as Licensing Deal for Peripheral Neuropathy Drug Nears	23-09-20	MT
Pharnext: expressions of interest received, share price soars	23-09-20	CF
Global markets live: Airbus, Goldman Sachs, CVS Health, US Steel, Boeing...	23-08-24

Pharnext SCA specializes in the development of drugs based on PleotherapyTM for the treatment of severe, rare and common neurological diseases (including Alzheimer, Charcot-Marie Tooth disease, Parkinson's and amyotrophic lateral sclerosis). The company keeps creating new treatments by combining, at very low doses, molecules that are already tested for other diseases. The group has a portfolio of 2 products in clinical development: PXT3003 (treatment of the orphan disease Charcot-Marie-Tooth type 1A) and PXT864 (Alzheimer's disease treatment).

Sector

Pharmaceuticals

Calendar

2024-10-16 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PHARNEXT SCA	-92.50%	27.82K
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Pharnext SCA

Equities

ALPHA

FR001400N1P4

Pharmaceuticals

Pharnext SA announced that it expects to receive ?1.5 million in funding

Latest news about Pharnext SCA

Chart Pharnext SCA

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Pharmaceuticals